NORTH : A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

<39Age Under 39

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Brain and spinal cord,SarcomaBrain,Central Nervous System,Neuroblastoma,Osteosarcoma,Sarcoma

Trial Overview Read MoreRead more

This phase II trial is testing the effectiveness of a new oral drug (Pabinostat) in paediatric and adult patients who have an osteosarcoma, rhabdoid tumour and/or neuroblastoma that has gotten worse or not responded to prior treatment.
 

This trial is treating multiple types of cancer including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours or Neuroblastoma.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma

Other Non-Commercial Sponsor

National Health & Medical Research Council (NHMRC)

Summary

Participants in this trial will be stratified according to their diagnosis; osteosarcoma, neuroblastoma and MRT/ATRT. Patients will be enrolled following the end of their conventional therapy, which may include chemotherapy and/or radiation treatment. Patients will have a three-week wash out period before commencing on the trial. Pabinostat will be administered as a continuous daily oral dose, and will follow a dose escalation scheme for each stratum, determined by biological effect of the drug. The final dose will be defined when significant biological effect is achieved with acceptable toxicity, and is maintained for a 4 week period.

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next